Published in Arterioscler Thromb Vasc Biol on December 29, 2011
High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res (2014) 1.04
Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep (2012) 0.90
GPR109A and vascular inflammation. Curr Atheroscler Rep (2013) 0.87
Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice. FASEB J (2013) 0.83
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res (2012) 0.82
Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol (2013) 0.80
Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant (2014) 0.77
Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One (2013) 0.77
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Rev Cardiovasc Ther (2013) 0.76
The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling. FASEB J (2015) 0.76
Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest (2015) 0.75
Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? Med Sci Monit (2015) 0.75
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation (1983) 12.63
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet (1975) 9.00
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Chemokines in the pathogenesis of vascular disease. Circ Res (2004) 4.64
Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys (1955) 3.63
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Inflammation in atherosclerosis: transition from theory to practice. Circ J (2010) 2.98
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand (1988) 2.86
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med (2005) 2.40
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
"Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet (2005) 2.24
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation (2007) 2.07
Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun (2003) 2.00
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol (2008) 1.97
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med (1989) 1.90
Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes (2005) 1.87
Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med (2001) 1.79
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia (2000) 1.73
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol (2009) 1.66
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest (2010) 1.64
Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation (2011) 1.55
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest (2011) 1.46
Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis (2008) 1.45
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther (2007) 1.39
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res (2004) 1.31
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis (2009) 1.31
Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol (2012) 1.29
Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab (2009) 1.25
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol (2007) 1.22
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol (2006) 1.19
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol (2010) 1.15
PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol (2001) 1.15
Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism (2003) 1.13
International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev (2011) 1.11
Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation (2011) 1.09
Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun (2005) 1.06
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J (2009) 1.04
Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens (2000) 1.02
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med (2000) 1.01
Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment. Metabolism (2010) 1.00
Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol (1999) 0.97
Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest (1996) 0.96
Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab (2000) 0.95
Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep (2000) 0.93
cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem Biophys Res Commun (2000) 0.91
Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug. J Clin Endocrinol Metab (2011) 0.90
Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes. Pharmacology (2009) 0.89
Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin Pharmacol Toxicol (2009) 0.83
Niacin: an old drug rejuvenated. Curr Atheroscler Rep (2009) 0.80
Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther (2011) 0.79
Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. Am J Cardiol (2004) 0.79
Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis. Immunobiology (2011) 0.79
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. Am J Cardiovasc Drugs (2011) 0.78
Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2004) 2.53
Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla. J Am Coll Cardiol (2012) 2.38
Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 2.34
Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2002) 2.13
Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson (2012) 2.03
Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage index. Circ Cardiovasc Imaging (2011) 1.97
In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med (2007) 1.90
Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol (2007) 1.86
Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol (2007) 1.78
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol (2009) 1.66
Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction. J Am Coll Cardiol (2014) 1.63
First-in-man transcatheter mitral valve-in-ring implantation with a repositionable and retrievable aortic valve prosthesis. EuroIntervention (2016) 1.39
Plaque features associated with increased cerebral infarction after minor stroke and TIA: a prospective, case-control, 3-T carotid artery MR imaging study. JACC Cardiovasc Imaging (2012) 1.35
Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation (2012) 1.32
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis (2009) 1.31
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (2003) 1.31
Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol (2012) 1.29
Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov (2008) 1.26
Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson (2014) 1.26
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging (2012) 1.18
Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation (2004) 1.12
Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci U S A (2012) 1.10
Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation (2013) 1.09
A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest (2008) 1.09
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis (2009) 1.08
In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components. J Cardiovasc Magn Reson (2013) 1.06
Quantification and 3D reconstruction of atherosclerotic plaque components in apolipoprotein E knockout mice using ex vivo high-resolution MRI. Arterioscler Thromb Vasc Biol (2004) 1.05
CMR for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol (2010) 1.04
Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 0.99
In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One (2010) 0.99
Diagnostic value of pre-contrast T1 mapping in acute and chronic myocardial infarction. JACC Cardiovasc Imaging (2013) 0.98
Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis (2007) 0.97
Reproducibility and accuracy of automated measurement for dynamic arterial lumen area by cardiovascular magnetic resonance. Int J Cardiovasc Imaging (2009) 0.97
Black-blood multicontrast imaging of carotid arteries with DANTE-prepared 2D and 3D MR imaging. Radiology (2014) 0.97
VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J (2011) 0.96
Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res (2007) 0.94
Myocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulus. Inflamm Res (2013) 0.94
Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res (2008) 0.94
Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: rational design through target quantification. Atherosclerosis (2011) 0.94
Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol (2009) 0.92
Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab (2010) 0.92
A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content. Arterioscler Thromb Vasc Biol (2012) 0.90
Loss of fine structure and edge sharpness in fast-spin-echo carotid wall imaging: measurements and comparison with multiple-spin-echo in normal and atherosclerotic subjects. J Magn Reson Imaging (2011) 0.89
Clopidogrel and percutaneous coronary interventions. JAMA (2003) 0.89
High-resolution, multicontrast three-dimensional-MRI characterizes atherosclerotic plaque composition in ApoE-/- mice ex vivo. J Magn Reson Imaging (2004) 0.87
GPR109A and vascular inflammation. Curr Atheroscler Rep (2013) 0.87
Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice. Am J Pathol (2013) 0.87
Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart (2006) 0.86
Magnetic resonance imaging and computed tomography in assessment of atherosclerotic plaque. Curr Atheroscler Rep (2004) 0.83
Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. Prog Brain Res (2009) 0.81
Development and application of endothelium-targeted microparticles for molecular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.81
Molecular MRI approaches to the detection of CNS inflammation. Methods Mol Biol (2011) 0.81
Multimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity. J Cardiovasc Magn Reson (2011) 0.80
Effects of niacin on atherosclerosis and vascular function. Curr Opin Cardiol (2011) 0.80
Magnetic resonance imaging of brain inflammation using microparticles of iron oxide. Methods Mol Biol (2011) 0.80
Ischemic heart disease: comprehensive evaluation by cardiovascular magnetic resonance. Am Heart J (2011) 0.79
Atherosclerosis regression and high-density lipoproteins. Expert Rev Cardiovasc Ther (2010) 0.79
The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. EuroIntervention (2016) 0.78
Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease. Int J Cardiol (2013) 0.78
Exogenous microparticles of iron oxide bind to activated endothelial cells but, unlike monocytes, do not trigger an endothelial response. Theranostics (2013) 0.78
Percutaneous retrieval of an embolized pacemaker lead from the pulmonary artery. Int J Cardiol (2009) 0.78
Target: ligand interactions of the vascular endothelium. Implications for molecular imaging in inflammation. Integr Biol (Camb) (2010) 0.78
Embolic myocardial infarction in atrial fibrillation: multiple territory injury revealed by cardiac magnetic resonance. Eur Heart J (2010) 0.78
A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention (2016) 0.78
Non-invasive imaging of carotid arterial restenosis using 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2014) 0.77
Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol (2005) 0.77
Targeted molecular imaging of vascular inflammation in cardiovascular disease using nano- and micro-sized agents. Vascul Pharmacol (2012) 0.77
The role of cardiovascular magnetic resonance in patients with acute coronary syndromes. Prog Cardiovasc Dis (2011) 0.77
Targeting HDL-cholesterol to reduce residual cardiovascular risk. Curr Opin Lipidol (2012) 0.77
Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One (2013) 0.77
Perioperative management of anticoagulation during device implantation-the UK perspective. Pacing Clin Electrophysiol (2010) 0.77
Detection of brain pathology by magnetic resonance imaging of iron oxide micro-particles. Methods Mol Biol (2011) 0.77
Minimal Acute Recoil Following Bioresorbable Scaffold Implantation in Fibrocalcific Lesion Detected by Optical Frequency-Domain Imaging. J Invasive Cardiol (2016) 0.76
Cardiometabolic interventions - focus on transcriptional regulators. Eur J Cardiovasc Med (2013) 0.76
3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO). JACC Cardiovasc Interv (2015) 0.76
The influence of coronary plaque morphology assessed by optical coherence tomography on final microvascular function after stenting in patients with ST-elevation myocardial infarction. Coron Artery Dis (2016) 0.75
Macrophage detection in aortic aneurysm: the heat is on. Arterioscler Thromb Vasc Biol (2011) 0.75
Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol (2017) 0.75
Rheumatoid arthritis: RA--lowering cardiovascular risk with statins. Nat Rev Rheumatol (2010) 0.75
Platelet inhibition with cangrelor. N Engl J Med (2010) 0.75
First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. JACC Cardiovasc Interv (2017) 0.75
Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)? Curr Opin Lipidol (2010) 0.75
Transfemoral Transcatheter Aortic Valve-in-Valve Implantation for Aortic Valve Bioprosthesis Failure With the Fully Repositionable and Retrievable Lotus Valve: A Single-Center Experience. J Invasive Cardiol (2017) 0.75
Transcatheter valve interventions: playground for cardiologists or cardiac surgeons? The cardiologist's view. EuroIntervention (2015) 0.75
High-density lipoproteins and cardiovascular disease: the plots thicken. Heart (2012) 0.75
Atherosclerosis regression. Curr Treat Options Cardiovasc Med (2008) 0.75
Transfemoral Treatment of a Paraprosthetic Mitral Leak and Mitral Bioprosthesis Failure Complicated by Embolization of In-Situ Vascular Plug. J Heart Valve Dis (2015) 0.75
Coronary Intervention Complicated by Pressure Wires Caught Within Stent Struts. J Invasive Cardiol (2017) 0.75
Percutaneous repair of an aortic paraprosthetic leak an alternative to reoperating. JACC Cardiovasc Interv (2008) 0.75
A primary cardiac sarcoma presenting with superior vena cava obstruction. Am J Emerg Med (2011) 0.75
Diagnosis of an abnormality of the left main coronary. Heart (2014) 0.75
Advances in antiplatelet therapy for acute coronary syndromes. Postgrad Med J (2012) 0.75